EUCTR2007-007669-20-DE进行中（未招募）不适用
A Double-Blind, Multiple Dose Titration Study to Investigate the Safety,Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses ofJNJ-37822681 in Male and Female Patients With Stable SchizophreniaProtocol 37822681SCH2003; Phase IIaEudraCT Number: 2007-007669-20
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium0 个研究点目标入组 36 人开始时间: 2008年3月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •·Male or female between 18 and 65 years of age, inclusive
- •·Female subjects must meet one of the following:
- •–postmenopausal (for at least 12 months),
- •–Surgically sterile, (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy)
- •–abstinent (per investigator’s judgement),
- •–if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], male partner sterilization),
- •before entry, and must agree to continue to use the same method of contraception throughout the study.
- •·Women of childbearing potential must have a negative serum b human chorionic gonadotropin (b hCG) pregnancy test at screening and admission
- •·Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug. For men that have been clinically determined to be infertile, this restriction is for 5 days after receiving the last dose of study drug.
- •·In- or outpatients with schizophrenia stably treated for at least 6 months with antipsychotic monotherapy (£ 200mg/d chlorpromazine equivalent dose) or stable for at least 3 months without drug therapy
- •·PANSS at screening < 60
- •·In the opinion of the investigator and in compliance with local regulations, the subject can be withdrawn from current antipsychotic medication.
- •·A known (by the site) history of schizophrenia of at least 12 months
- •·BMI between 18 and 35 kg/m2 inclusive (BMI = weight/height2)
- •·Willing to be hospitalized during the double-blind treatment period of the study (up to Day 15).
- •·Willing to adhere to the prohibitions and restrictions specified in this protocol
- •·Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •·A DSM-IV axis I diagnosis other than schizophrenia
- •·A DSM-IV diagnosis of substance dependence within 6 months prior to screening evaluation (nicotine and caffeine dependence are not exclusionary)
- •·Any medical condition that could potentially alter the absorption, metabolism, or excretion of the study medication, such as Crohn’s disease, liver disease, or renal disease
- •·Relevant history of any significant and/or unstable cardiovascular, respiratory, neurologic (including seizures or significant cerebrovascular), renal, hepatic, endocrine, or immunologic diseases
- •·History of neuroleptic malignant syndrome (NMS)
- •·Other significant and/or unstable systemic illnesses
- •·Allergy or hypersensitivity to any known antipsychotic compounds
- •·Inability to swallow the study medication whole with the aid of water (subjects may not chew, divide, dissolve, or crush the study medication, as this may affect the release profile)
- •·Exposure to an experimental drug or experimental medical device within 90 days before screening
- •·Significant risk of suicidal or violent behavior
- •·Female subjects who are pregnant or breastfeeding
- •·Alanine aminotransferase or aspartate aminotransferase levels more than 2 times the upper limit of normal
- •·Other biochemistry, hematology, or urinalysis results that are not within the laboratory’s reference range, and that are deemed by the investigator to be clinically significant
- •·Use of beta-blockers (if used for any indication other than hypertension and still present at baseline)
- •·Injection of a depot antipsychotic within 120 days before screening, or use of paliperidone palmitate within 10 months before screening
- •·Use of fluoxetine or monoamine oxidase inhibitors within 4 weeks before screening
- •·Use of all other antidepressants, anticonvulsants, or lithium within 2 weeks before baseline
- •·Received electroconvulsive therapy within 3 months before screening
- •·Have been involuntarily committed to psychiatric hospitalization
- •·Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study
- •·Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
研究者
相似试验
进行中（未招募）
1 期
A Double-Blind, Multiple Dose Titration Study to Investigate the Safety,Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses ofJNJ-37822681 in Male and Female Patients With Stable SchizophreniaProtocol 37822681SCH2003; Phase IIaEudraCT Number: 2007-007669-20JNJ-37822681Amendment INT-1SchizophreniaEUCTR2007-007669-20-SKJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium36
进行中（未招募）
不适用
A Double-Blind, Multiple Dose Titration Study to Investigate the Safety,Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses ofJNJ-37822681 in Male and Female Patients With Stable SchizophreniaProtocol 37822681SCH2003; Phase IIaEudraCT Number: 2007-007669-20JNJ-37822681Amendment INT-1/SWE-2Site Specific-227 February 2008Incorporating Amendment INT-1/SWE-2/SS-2 – 23 April 2008SchizophreniaEUCTR2007-007669-20-SEJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium36
进行中（未招募）
不适用
A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stable SchizophreniaSchizophreniaEUCTR2007-007669-20-BEJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium36
已完成
不适用
A Double Blind, Ascending Multiple Dose Study to Evaluate the Safety and Tolerability of GAL-021 in Healthy Volunteers.Breathing problemsRespiratory impairment10038716NL-OMON41554Galleon Pharmaceuticals, Inc36
进行中（未招募）
不适用
A Double-Blind, Randomised, Dose-Ranging Study to Compare K-832 with Placebo in the treatment of Patients with Active Rheumatoid Arthritis - N/AMedDRA version: 6.0Level: LLT Classification code 10028395Rheumatoid ArthritisEUCTR2004-000362-12-CZKowa Research Europe Ltd260